Myeloid engraftment, GVHD, and DFS with URD marrow transplantation
. | Reference no. . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | 38 . | 51 . | . | . | . | 63 . | 41 . | ||||||
| General characteristics | NMDP (1987-1990), 462 patients, malignant and nonmalignant diagnoses | IBMTR (1985-1991), leukemia only | HLA-6/6 sibling donor (n = 1224) | HLA-5/6 or 4/6, related donor (n = 340) | URD (n = 491) | Seattle (1985-1993), 88 pediatric patients, malignant and nonmalignant diagnoses | NMDP (1988-1996), 1423 patients, chronic myeloid leukemia only | ||||||
| Age range, y (median) | 0.3-54.5 (26.0) | 1.0-57.0 (32) | 1.0-53.0 (25) | 1.0-56.0 (31) | 0.5-17.8 (9.1) | 0-20: 11% | |||||||
| 21-40: 54% | |||||||||||||
| > 40: 35% | |||||||||||||
| Myeloid engraftment,* % (median time, d) | 94 (22) | 99 | HLA-5/6: 91 | 91 | 93 (21) | 92 (20) | |||||||
| HLA-4/6: 84 | |||||||||||||
| Acute GVHD II to IV, % (III-IV) | 64 (47) | 29 (13) | HLA-5/6: 44 (27) | HLA-6/6: 54 (35) | HLA-6/6: 83 (37) | 43 (33) | |||||||
| HLA-4/6: 56 (36) | HLA-5/6: 63 (47) | HLA-5/6: 98 (62) | |||||||||||
| Chronic GVHD, % (extensive) | 55 (35) | 42 | HLA-5/6: 52 | HLA-6/6: 62 | HLA-6/6: 60 | 73 (60) | |||||||
| HLA-4/6: 60 | HLA-5/6: 73 | HLA-5/6: 69 (37) | |||||||||||
| DFS, % | 2-year DFS for leukemia, n = 352 | 3-year DFS | 3-year DFS | 3-year DFS | 3-year DFS | 3-year DFS: | |||||||
| Low risk = 40 | Low risk: 66 | HLA-5/6 | HLA-6/6 | CML: 75 | All patients in CP: 43; < 35 years, CP, < 1 year after diagnosis: 63 | ||||||||
| High risk = 19 | High risk: 12 | Low risk: 33 | Low risk: 41 | Acute leukemia | |||||||||
| High risk: 15 | High risk: 11 | Low risk ALL: 47 | |||||||||||
| HLA-4/6 | HLA-5/6 | High risk ALL: 10 | |||||||||||
| Low risk: 25 | Low risk: 26 | All AML: 46 | |||||||||||
| High risk: 22 | High risk: 17 | Others: 29 | |||||||||||
. | Reference no. . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | 38 . | 51 . | . | . | . | 63 . | 41 . | ||||||
| General characteristics | NMDP (1987-1990), 462 patients, malignant and nonmalignant diagnoses | IBMTR (1985-1991), leukemia only | HLA-6/6 sibling donor (n = 1224) | HLA-5/6 or 4/6, related donor (n = 340) | URD (n = 491) | Seattle (1985-1993), 88 pediatric patients, malignant and nonmalignant diagnoses | NMDP (1988-1996), 1423 patients, chronic myeloid leukemia only | ||||||
| Age range, y (median) | 0.3-54.5 (26.0) | 1.0-57.0 (32) | 1.0-53.0 (25) | 1.0-56.0 (31) | 0.5-17.8 (9.1) | 0-20: 11% | |||||||
| 21-40: 54% | |||||||||||||
| > 40: 35% | |||||||||||||
| Myeloid engraftment,* % (median time, d) | 94 (22) | 99 | HLA-5/6: 91 | 91 | 93 (21) | 92 (20) | |||||||
| HLA-4/6: 84 | |||||||||||||
| Acute GVHD II to IV, % (III-IV) | 64 (47) | 29 (13) | HLA-5/6: 44 (27) | HLA-6/6: 54 (35) | HLA-6/6: 83 (37) | 43 (33) | |||||||
| HLA-4/6: 56 (36) | HLA-5/6: 63 (47) | HLA-5/6: 98 (62) | |||||||||||
| Chronic GVHD, % (extensive) | 55 (35) | 42 | HLA-5/6: 52 | HLA-6/6: 62 | HLA-6/6: 60 | 73 (60) | |||||||
| HLA-4/6: 60 | HLA-5/6: 73 | HLA-5/6: 69 (37) | |||||||||||
| DFS, % | 2-year DFS for leukemia, n = 352 | 3-year DFS | 3-year DFS | 3-year DFS | 3-year DFS | 3-year DFS: | |||||||
| Low risk = 40 | Low risk: 66 | HLA-5/6 | HLA-6/6 | CML: 75 | All patients in CP: 43; < 35 years, CP, < 1 year after diagnosis: 63 | ||||||||
| High risk = 19 | High risk: 12 | Low risk: 33 | Low risk: 41 | Acute leukemia | |||||||||
| High risk: 15 | High risk: 11 | Low risk ALL: 47 | |||||||||||
| HLA-4/6 | HLA-5/6 | High risk ALL: 10 | |||||||||||
| Low risk: 25 | Low risk: 26 | All AML: 46 | |||||||||||
| High risk: 22 | High risk: 17 | Others: 29 | |||||||||||
Results of selected large studies are shown.
DFS indicates disease-free survival; NMDP, National Marrow Donor Program; IBMTR, International Bone Marrow Transplant Registry; HLA-6/6, HLA matched donor; HLA-5/6 and HLA-4/6, donor-recipient mismatch for 1 or 2 HLA-A, HLA-B, or HLA-DRB1, respectively; and CP, chronic phase.
Myeloid engraftment was defined as absolute neutrophil count > 0.5 × 109/L, first of 3 consecutive days.